News
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings
Digest more
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results